Lyophilized Cyclophosphamide Hydration for Uniform Moisture Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of cyclophosphamide (CPP) is affected by moisture content, with anhydrate forms being unstable at elevated temperatures or low humidity, and monohydrate forms losing crystal water in dry environments, making it difficult to maintain uniform moisture content during commercial production.
Innovation Solution
A method involving the preparation of an aqueous solution with cyclophosphamide and optional excipients, followed by freeze-drying and hydrating the freeze-dried composition with liquid water to achieve a controlled moisture content of 2-7% in the hydrated cyclophosphamide freeze-dried composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If freeze-drying process is used to remove moisture, then storage stability is improved, but uniform moisture content control becomes difficult
Solution Approach 1:
The patent applies preliminary action by pre-calculating and pre-setting the hydration time for each bottle size before production. The hydration parameters (time, temperature, humidity) are determined in advance based on bottle specifications, ensuring uniform moisture content across all bottles without requiring complex real-time control during the hydration process.
Solution Approach 2:
The patent changes the physical state parameter from anhydrous to monohydrate form through controlled hydration. By adjusting the hydration time parameter according to bottle size, the process transforms the chemical form of cyclophosphamide while maintaining uniform moisture content, thereby improving both storage stability and manufacturing precision.
2Adaptability or versatility
If anhydrous form is used, then storage at low humidity is possible, but stability at elevated temperature deteriorates
Solution Approach 1:
The patent changes the chemical composition parameter by converting anhydrous cyclophosphamide to monohydrate form through controlled hydration. This parameter change improves thermal stability while the product can still be stored at different humidity levels, maintaining adaptability to various storage conditions.
Solution Approach 2:
The patent applies beforehand cushioning by pre-hydrating the cyclophosphamide to monohydrate form before packaging. This preliminary hydration protects the substance from thermal degradation during storage and transport, cushioning against the harmful effects of elevated temperatures without requiring strict humidity control.
3Reliability
If monohydrate form is used, then stability is improved, but crystal water loss occurs in dry environment
Solution Approach 1:
The patent optimizes the moisture content parameter to a specific range (3-8%) that maintains the monohydrate form's chemical stability while preventing crystal water loss. By controlling the hydration process to achieve this precise parameter range, the product maintains both stability and compositional integrity in dry storage environments.
Solution Approach 2:
The patent creates a controlled microenvironment within the packaging by incorporating moisture-generating materials that maintain the required humidity level. This copying of the hydration conditions prevents crystal water loss from the monohydrate form while preserving its chemical stability during storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method stabilizes cyclophosphamide by maintaining a consistent moisture content, enhancing its stability and redissolving properties, ensuring consistent product quality and efficacy.
Implementation Method 1
freeze-drying the aqueous solution to give a freeze-dried composition
Implementation Method 2
hydrating the freeze-dried composition with liquid water to give the hydrated Cyclophosphamide freeze-dried composition
Data Source
AI summary
Provided are a hydration method for a lyophilized cyclophosphamide composition and a composition and preparation prepared thereby. The hydration method comprises: (a) providing an aqueous solution comprising cyclophosphamide and an optional pharmaceutically acceptable excipient; (b) freeze-drying the solution to obtain a lyophilized composition; and (c) hydrating the lyophilized composition by using liquid water to obtain the product.